Nuvation Bio (NUVB) Common Equity (2020 - 2026)

Nuvation Bio (NUVB) has reported Common Equity for 7 consecutive years, with $319.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 23.82% year-over-year to $319.6 million; the TTM figure through Mar 2026 stood at $319.6 million (down 23.82% YoY), while the FY2025 annual figure was $305.7 million, down 34.08% from the prior year.
• Common Equity advanced to $319.6 million in Q1 2026 per NUVB's latest filing, from $305.7 million in the prior quarter.
• Across five years, Common Equity topped out at $723.6 million in Q1 2022 and bottomed at $257.2 million in Q2 2024.
• Historically, Common Equity has averaged $516.7 million across 5 years, with a median of $594.0 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity plunged 58.82% — and 2025, when it surged 44.99%.
• Nuvation Bio's Common Equity stood at $655.1 million in 2022, then dropped by 7.63% to $605.1 million in 2023, then retreated by 23.36% to $463.8 million in 2024, then sank by 34.08% to $305.7 million in 2025, then gained by 4.53% to $319.6 million in 2026.
• Business Quant data shows NUVB's Common Equity at $319.6 million in Q1 2026, $305.7 million in Q4 2025, and $325.9 million in Q3 2025.